2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.
Attendees at the 6th Annual Interdisciplinary Prostate Cancer Congress gathered in New York City on March 16 to review the latest strategies and therapeutic agents available for patients with the disease, and to build consensus about their application. In the wake of the approval of several novel treatments for prostate cancer—including anti-androgens enzalutamide and abiraterone and immunotherapy sipuleucel-T — a special focus this year was “Integrating New Therapies into the Prostate Cancer Continuum.”
Panel and audience members considered several case studies and discussed the treatment options they thought were best. The cases were presented by event co-chair Leonard G. Gomella, MD, and discussed by a panel that included co-chair Daniel P. Petrylak, MD; Robert Dreicer, MD, MS; E. David Crawford, MD; and Susan F. Slovin, MD.
Gomella: The patient is a 55-year-old white male. His father died of prostate cancer at 65 years of age, and no other family members have any history of prostate cancer. The patient is worried and wants to be checked, although he’s done some reading and is doubtful about the value of the prostate-specific antigen (PSA) test. What do you tell him?
Dreicer: The patient is at risk since he had a first-degree relative who was impacted. Screening is reasonable for him.
Petrylak: I’d tell him that PSA has its implications. If it’s elevated, he’ll need a biopsy, and then he’ll have to choose either local therapy or observation. I would do it if I were him. But he needs to know what the studies say.
Slovin: I would explain the pros and cons and then leave it up to him, although I probably would give him the strong arm because his risk is at least two-fold higher than John Doe’s next door as a result of his family history. I’d also make sure he’s had a screening colonoscopy.
Crawford: One family member probably doesn’t increase your risk a lot. You’ve got to have two or three to be at a higher risk.
Gomella: The patient has his PSA tested and it’s deemed normal at 1.1 His digital rectal exam is normal. Can you tell him he doesn’t have prostate cancer?
Crawford: No. Based on the results of the Prostate Cancer Prevention Trial [in which 15% of men with PSAs of <4 ng/mL were found to have prostate cancer],1 he still faces a risk. I’d do a prostate cancer gene 3 (PCA3) test on him.
Gomella: Even though he hasn’t had a biopsy yet, you would jump the fence on the PCA3 and use it sort of off-label? The labeled indication is to see if a second biopsy is needed.
Gomella: What I tell my residents—and my patients—is that we’re finding our way with PCA3, but that we have a lot of questions. Still, I’d rather have a PCA3 in the bank in case some breakthrough comes up over the next couple of years.
Which of the following treatment options would you recommend in this setting?
So, you can’t tell the patient he doesn’t have prostate cancer. What would you do next?
Slovin: I would ask him to repeat a PSA in a short period of time to get a sense of how rapidly it’s going up.
Gomella: Let’s assume he had a biopsy a year ago that was completely normal. Now he comes in and his PSA has gone up to 5. He still has a normal digital rectal exam. What would you do next?
Petrylak: He needs a repeat biopsy. I would do a saturation biopsy.
Gomella: How about PCA3, if he didn’t have it before?
Petrylak: It probably would be appropriate, but I still think he’s going to need a biopsy.
Gomella: What about free-to-total PSA? Is anyone using that anymore? We asked this question two years ago and just about everybody put their hands up, and now, as I look around, there seems to be a lot of cooled enthusiasm.
Petrylak: I’d do a PCA3 first, though.
Gomella: I agree, although it does scare me a little bit that his PSA has had such a rapid rise.
Crawford: The PCA3 would make me feel better about doing another biopsy.
Gomella: The patient comes back three years later and his PSA is up to 8. He’s had at least three sets of 12-core biopsies, and they’ve all been negative. Now where are we?
Crawford: This is a guy that I would get the MRI on, and the mapping biopsies. I’d also consider the fact that, every time you have one negative biopsy, your risk goes down. If the guy is tired of biopsies or his insurance company won’t pay for more, I’d also think about putting him on dutasteride to see what his PSA does, because I’ve seen people like this go from 8 to 1 again, or at least cut their PSA in half.
Gomella: Dave, what about transurethral (TUR) biopsy? We used to do that in the ’90s when we ran into this situation. It was sort of an anterior biopsy. Is this a dead issue now because of MRIs?
Crawford: A lawyer told me the other day that he’s defending a urologist for that very thinking. The patient was just like this one: negative biopsy, negative biopsy, negative biopsy, PSA not even up this high, and so he didn’t do anything. A couple of years later he’s got metastatic disease, and they’re saying he should have had a TUR biopsy. But to me, what takes the place of the TUR biopsy are the staging and mapping biopsies. We’ve actually shown that if you take those biopsies and you correlate them to whole mount radical prostatectomy specimens, they’re just as accurate, if not more accurate, at predicting what’s there.
Audience member: I have a question about PSA leaks in people who’ve had multiple biopsies. I’ve certainly done three or four biopsies on people, but I worry that I have created the [elevated] PSA with all the [needle] sticks.
Gomella: Dave, with all those needle sticks in the prostate, are you making a leaky prostate, making neovascular channels when it heals and sending more PSA out to the bloodstream?
Crawford: I don’t buy it.
Gomella: There’s some data out there now saying that the more biopsies you have, the more difficult it may be to spare nerves when you get treated definitively with a radical prostatectomy. What do you think about that, Dave?
Crawford: Well, I’ve had a lot of experience in going in after mapping. Since the mapping is done transperineally, it’s not much more difficult to do. In the people that have had a couple of what you described as saturation biopsies, which are transrectal, that has been difficult.
Gomella: So, what can a patient like this do to prevent prostate cancer, and what should you recommend?
Slovin: There is data that there is some benefit to changing the diet, limiting the amount of red meat. And while I recommend that for some patients who are on the heavier side, I don’t know that it’s something we would do for everybody. The question is, do I put him on dutasteride or finasteride? I’d be a little worried, but you can make an argument that if the prostate shrinks down a little bit more it’s going to be easier to find a Gleason 8 or 9 cancer sitting there waiting for us.
Gomella: It’s kind of disappointing that we don’t have this as an approved prevention strategy, since we have two large clinical trials that show a 20% to 25% relative risk reduction with 5 alpha-reductase inhibitors, and data from trials such as CombAT2 demonstrating no increased risk of high-grade cancer. Dr Dreicer, you’ve been involved in some drug discussions at the FDA level. Do you think there’s any chance that this thing could get resurrected?
Crawford: Less than none. We’ve been through so many things on the prevention of prostate cancer: vitamin E, and selenium, and saw palmetto, and the 5-alpha reductase inhibitors, and Vioxx. I think the benefit of 5-alpha reductase inhibitors is real, but we also need to document the risk of high-grade cancer, which is probably volume-related. In my opinion, chemoprevention trials in prostate cancer are dead because it’s too risky.
Gomella: You may also be familiar with the data that came out a few years ago that patients with advanced prostate cancer who went on hyper-vitamin therapy actually had a worse outcome. They progressed more rapidly. So, we have to convince our patients that more is not necessarily better.
Petrylak: That was demonstrated in the SELECT trial3 too. The trial took all comers, and you wonder what giving these vitamins at high dosages to somebody who has a normal level is going to do to their prostate tissue. A lot of these agents are “yin-yang”: In low doses they may be inhibitory, in high doses they may be stimulatory. So when designing these studies in the future, you’re going to have to look at levels and see whether you’re supplementing something that doesn’t need to be supplemented.
Gomella: And despite these data, we still find all our patients taking vitamin E and selenium to prevent prostate cancer, which is really sad.
Gomella: The patient is a 62-year-old who develops urinary frequency. His primary care doctor detects a nodule on rectal exam and a PSA of 82. A urologist does a biopsy and finds Gleason 7 cancer. A bone scan shows four lesions in the lumbar sacral spine, and a CT scan of the abdomen shows retroperitoneal lymphadenopathy. The patient undergoes combined androgen blockade. His PSA bottoms out at less than 0.1 seven months after the blockade is started, and he remains on continuous androgen blockade for about three years. His PSA then begins to slowly rise from 0.2 to 0.8 to 1.0 over a six-month period. On bone scan, progression is noted with two more spots in the ribs. A CT scan of the abdomen and pelvis shows resolution of retroperitoneal adenopathy, and the patient feels pretty good. He’s not in any pain, and he has a good appetite and a good performance status.
At this point, what would you do?
Petrylak: The only times I’ve used ketoconazole in a patient who’s castrate resistant is when the patient has nonmetastatic disease. Except in that situation, abiraterone has superseded ketoconazole in this clinical state.
Slovin: I’ve gone back to ketoconazole because abiraterone is not always covered by insurance. Ketoconazole is not as effective, and it has more toxicity, but if you’re in a dither it’s the best one to use. On this particular patient, though, I could make the argument that if he went into a complete biochemical radiographic remission, I would have radiated his prostate for local control and maybe used adjuvant hormones for an extra year, and then gotten him off everything. He’s a young guy, and the law does not say one should stay on hormones for ever and ever.
Dreicer: Clearly we’re going to stop his bicalutamide—that’s a no brainer—and if you’re going to think about immunomodulatory therapy, this might be a very good patient to use it in. Even if he has an antiandrogen withdrawal response, you could argue that that’s okay, and may make him even a better candidate.
Gomella: The patient’s testosterone is 55 and he’s been getting leuprolide. What would you do at that point?
Petrylak: One option would be to put him on abiraterone, which would reduce his testosterone even further. A second would be to put him on degarelix, which could also lower his testosterone. Of course, the final option is simply to do an orchiectomy.
Your next treatment choice is:
Gomella: An important point, and one that Dr Crawford has been out in the lead on, is that our LHRH analog therapies are one-size-fits-all. If you have a 98-pound gentleman and a 300-pound gentleman, they get the same dose of the LHRH analog, and there are some issues now to suggest that the mode of administration and obesity can actually affect absorption and utility. So, at our shop, we’ve flipped people from goserelin to triptorelin, or triptorelin to leuprolide, and I have to say that we’ve always gotten their testosterone to come down.
Crawford: In a study, we looked at patients with testosterone less than 50 who went on sipuleucel-T, and then [investigational] GTx-758 and a couple of other agents, and watched testosterone levels. Twenty-one percent of participants had testosterone levels above about 20. Orchiectomy gets you to 14 to 17. And so, theoretically, these patients aren’t castrate. And maybe the reason 20% to 30% of people respond to secondary androgen ablation is because they weren’t totally suppressed to begin with.
Slovin: While we’re getting serum testosterone levels down, we still are never 100% sure of intratumoral testosterone levels. That’s always sitting in the background.
Dreicer: And the testosterone assays most of us use in the hospitals are not very sensitive, especially at the low level.
Crawford: You’ve got to also measure the free testosterone level.
Gomella: The patient gets sipuleucel-T and, at one month post-therapy, his PSA continues to rise to 20 and then to 30. His bone scan is stable with no new lesions. He has no complaints and feels well. Six months later, his bone scan stays stable and his PSA goes up to 50. What would you tell him now about the sipuleucel-T?
Slovin: I would tell him that we don’t know how long it takes to see a propitious antitumor response, and as long as his cancer is stable, it’s fine.
Gomella: In this case, the patient was put on abiraterone and prednisone. Do you think he needed to be there, Rob?
Dreicer: I would have been concerned that, in a relatively short period of time, he was going to become symptomatic, and I’d want to obviate that, so I think it’s eminently reasonable to have treated him.
Gomella: So the patient is put on the abiraterone/prednisone regimen, and his PSA goes down. Eight months after treatment, it’s down to 3. However, it then goes up to 5 and then, four weeks later, to 9. He has new or recurring retroperitoneal adenopathy. His bone scan shows more lesions, and he has lumbosacral spine pain. He’s failed hormonal therapy, sipuleucel-T, and abiraterone.
Gomella: It looks like the clear winner here is standard docetaxel and prednisone. Dan, any comments about using it in the setting of having pain?
Petrylak: The right situation to use it is when the patient is symptomatic. As far as your alternatives, there’s no data for using cabazitaxel in the frontline setting. With enzalutamide, we don’t know what the response rate is after abiraterone. Also, at this point, it’s not approved for that indication.
Gomella: The patient is 69 years old and has Gleason 4+3 prostate cancer. His PSA is 9, and his rectal exam shows a T2a nodule. He is staged negative on bone scan and CAT scan, has good GU function, and is sexually active without PDE-5 inhibitors. He has had no previous pelvic radiation or irritable bowel disease, and his prostate size is about 40 ccs on transrectal ultrasound.
Since he prefers radiation therapy, his options are:
Gomella: Dr. Crawford, what are your thoughts on this gentleman?
Crawford: I think he has all of those things available. The current “sexy treatment” seems to be focusing on brachytherapy and how high the dose can go. So that’s what a lot of people are doing.
Gomella: Probably mixing brachytherapy with external beam would be a top option for him. But it’s almost dealer’s choice.
Gomella: We’re going to assume this man is intermediate or higher-intermediate risk, and that’s probably a reasonable choice. Dave, do you have any thoughts about using an LHRH agonist or antagonist in these settings? Are you still using combined androgen blockade?
Crawford: I still believe in combined androgen blockade. If you give an agonist, you get a flare, testosterone goes up, the tumor gets bigger, and the prostate gets bigger. If you’re trying to downsize, you’re wasting time. So, combined androgen blockade makes sense. There’s pretty good evidence about using an antagonist where you don’t get that, and some other advantages. So, we tend to use more antagonist activity.
The other trend that’s interesting is that the hormone therapy is kind of going away, except in really high-risk patients, and that it’s being continued for less than 2 years, while the radiation dose is going up. The claim is that there’s less local failure because we’re able to get the gray up so high. But I don’t buy that. My argument is that a lot of these people who are getting hormones and radiation with intermediate and advanced disease are actually benefiting from treatment of micrometastatic disease with hormone therapy.
Gomella: The other question that has been unanswered is: How many of these patients actually recover their testosterone level to some reasonableness? That’s something that the radiation/ oncology community has not been enthusiastic about studying because they think it’s not an important issue.
Crawford: Another thing that never gets talked about is that when you radiate the prostate, you have radiation scatter that hits the testes and lowers testosterone. If you look at a few studies that have been done, the bump in testosterone down is not huge. It’s 10%, 20%, maybe even more. What effect does that have?
If you were going to treat this man with external-beam radiation monotherapy, what would be the optimum dose he should receive for localized prostate cancer?
Gomella: Once you start getting to 80 Gy with external-beam radiation, the toxicity goes up dramatically.
Audience member: What’s your opinion about local radiation at this point? Not the complete gland, but focal radiation?
Crawford: I think it’s a good idea to do extra loading of the seeds in the area that is involved, and then not as much to cover the rest of the gland.
Gomella: It might make theoretic sense from a standard of care standpoint, but it’s nowhere in any kind of guidelines.
Crawford: They’re actually doing it at Memorial Sloan-Kettering. And we’re going to be joining them in a trial that will involve targeting, loading it to the lesion.
Gomella: High-dose radiation therapy is being reconsidered in localized prostate cancer, as well. We’re not talking about focal therapy there, but it’s just another way of getting the radiation into the gland.